Neutral
Vertrix Wealth Management LLC bought a new stake in Eli Lilly and Company (NYSE:LLY – Free Report) during the first quarter, HoldingsChannel.com repor...
Neutral
Trust Investment Advisors cut its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 4.6% during the first quarter, Holdings Chan...
Bullish
Eli Lilly and Co's stock (LLY) surged by 3.06% on July 2, driven by several key developments. These include the launch of a Medicare GLP-1 Bridge prog...
Neutral
Diamant Asset Management Inc. raised its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 119,923.8% during the first quarter, according ...
Eli Lilly and Company (LLY) plans to launch its oral weight-loss drug in Europe and Britain in late 2026 or early 2027, targeting direct-to-patient sa...
Eli Lilly's stock saw a significant jump of 6.3% today due to two major positive developments: the European Medicines Agency's committee backed its ca...
Eli Lilly and Co (LLY) stock rose by 6.15% on June 26, driven by several factors including a positive recommendation from the EMA for its oncology dru...
Neutral
Oak Family Advisors LLC trimmed its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 60.6% during the first quarter, according to its most r...
Neutral
Focused Wealth Management Inc lifted its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 119.5% in the first quarter, HoldingsChannel.com r...
Neutral
BCS Wealth Management reduced its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 49.9% in the 1st quarter, Holdings Channel reports. Th...
Neutral
James J. Burns & Company LLC lifted its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 78.5% in the 1st quarter, according to the company ...
Neutral
Evolve Private Wealth LLC lifted its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 44.7% during the first quarter, Holdings Channel re...
Neutral
This article argues that investors should consider Pfizer (NYSE:PFE) over Eli Lilly (NYSE:LLY), especially given current market volatility. While Eli ...
Eli Lilly EVP Ilya Yuffa sold 2,500 shares of common stock at an average price of $1,150.77 per share on June 10, 2026, as part of a pre-arranged Rule...
Abridge, an AI clinical assistant company, has secured a strategic investment from Eli Lilly and expanded its platform to integrate payer and life sci...
This SEC filing is a Form 144 Notice of Proposed Sale of Securities for ELI LILLY & Co (LLY). The filing indicates an intent to sell 2500 shares of co...
Eli Lilly's stock reached a new record high following positive data released for its next-generation weight-loss drug, retatrutide. This development h...
Eli Lilly and Co (LLY) experienced a 3.37% stock increase on June 8, driven by positive late-stage clinical trial results for its investigational trip...
Neutral
Prudent Man Advisors LLC grew its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 103.3% during the fourth quarter, according to its most r...
Neutral
Havemeyer Place LP bought a new position in Eli Lilly and Company (NYSE:LLY – Free Report) in the fourth quarter, according to its most recent disclos...